Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer
Status:
Withdrawn
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose to totally abolish the emesis (vomiting) associated with the
regimen of oxaliplatin + topotecan by adding a daily administration of aprepitant (Emend) for
17 days to the HT3 blocker routinely given on days 1 and 15.
Phase:
N/A
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health